Current Report Filing (8-k)
May 31 2019 - 4:09PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
May 31, 2019
Date of
Report (Date of earliest event reported)
Synthorx,
Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-38756
|
|
46-4709185
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
11099 N. Torrey Pines Road, Suite 190
La Jolla, California
|
|
92037
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (858)
750-4700
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, par value $0.001 per share
|
|
THOR
|
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§ 230.405 of this chapter) or Rule 12b2 of the Securities Exchange Act of 1934 (§ 240.12b2 of this chapter).
Emerging growth
company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 7.01.
|
Regulation FD Disclosure.
|
Starting on June 1, 2019, members of the management team of Synthorx, Inc. will be presenting a poster (the Poster) at the 2019 American
Society of Clinical Oncology Annual Meeting. A copy of the Poster is attached as Exhibit 99.1 to this Current Report on Form
8-K
and incorporated herein by reference.
The information in this Item 7.01 of this Current Report on Form
8-K,
including Exhibit 99.1, is being furnished
pursuant to Item 7.01 and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, and it shall
not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this
item of this report. This Current Report on Form
8-K
will not be deemed an admission as to the materiality of any information in this Current Report on Form
8-K
that is
being disclosed pursuant to Regulation FD.
Item 9.01
|
Financial Statements and Exhibits.
|
(d)
Exhibits
.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Synthorx, Inc.
|
|
|
|
|
Dated: May 31, 2019
|
|
|
|
By:
|
|
/s/ Laura Shawver
|
|
|
|
|
|
|
Laura Shawver, Ph.D.
|
|
|
|
|
|
|
President and Chief Executive Officer
|
Synthorx (NASDAQ:THOR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Synthorx (NASDAQ:THOR)
Historical Stock Chart
From Sep 2023 to Sep 2024